ArticleInternational journal of nephrology and renovascular disease2011
Tolvaptan, hyponatremia, and heart failure.
Article in International journal of nephrology and renovascular disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- The role of tolvaptan add-on therapy in patients with acute heart failure: a systematic review and network meta-analysis.Frontiers in cardiovascular medicine · 2024Pooled it
- Clinical trial on the pharmacokinetics, pharmacodynamics and safety of tolvaptan in healthy Chinese males: an open-label, single and multiple dosage, parallel group study.Frontiers in pharmacology · 2025Trial
- Development of Orally Disintegrating Tablets from Solid Dispersions Containing Tolvaptan/Cyclodextrin ComplexesTurkish journal of pharmaceutical sciences · 2026Article
- Severe tolvaptan-associated hyperglycemia: a case report.Journal of medical case reports · 2025Article
- Management of Hyponatremia in Heart Failure: Practical Considerations.Journal of personalized medicine · 2023Review
- Tolvaptan Add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction (DR-AHF): Design and Rationale.Frontiers in cardiovascular medicine · 2021Article
- Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects.Molecular medicine (Cambridge, Mass.) · 2020Review
- Severe Symptomatic Hyponatremia Secondary to Escitalopram-Induced SIADH: A Case Report with Literature Review.Case reports in nephrology · 2018Article
- Efficacy of oral tolvaptan versus 3% hypertonic saline for correction of hyponatraemia in post-operative patients.Indian journal of anaesthesia · 2017Article
- Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model.Journal of clinical biochemistry and nutrition · 2017Article
- Potential Effectiveness of Tolvaptan to Improve Ascites Unresponsive to Standard Diuretics and Overall Survival in Patients with Decompensated Liver Cirrhosis.Clinical drug investigation · 2016Article
- Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients.World journal of gastroenterology · 2016Article
- Volume control in treatment-resistant congestive heart failure: role for peritoneal dialysis.Heart failure reviews · 2014Review
- Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.Journal of neuroendocrinology · 2012Review
- V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.The Journal of biological chemistry · 2012Article
- Efficacy of vaptans for correction of postoperative hyponatremia: A comparison between single intravenous bolus conivaptan vs oral tolvaptan.Journal of anaesthesiology, clinical pharmacologyArticle
- Novel Use of Tolvaptan in a Pediatric Patient With Congestive Heart Failure Due to Duchenne Muscular Dystrophy and Congenital Adrenal Hyperplasia.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAGArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tolvaptan is the first FDA-approved oral V(2) receptor antagonist for the treatment of euvolemic and hypervolemic hyponatremia, in patients with conditions associated with free water excess such as heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion. Tolvaptan inhibits the binding of arginine vasopressin to the V(2) receptors on the collecting ducts of the kidneys resulting in aquaresis, the electrolytes sparing excretion of water. This article reviews the accumulated experience with tolvaptan and all the major clinical trials that were conducted to study its safety and efficacy and concludes by summarizing clinicians' views of its current application in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.